Skip to main content
Premium Trial:

Request an Annual Quote

Genomenon, Deep 6 AI Forge Data Partnership for Clinical Trial Matching

NEW YORK – Genomenon said Thursday that it has entered into a data partnership with Deep 6 AI, a maker of artificial intelligence-based clinical trial acceleration software.

Under what the firms dubbed a proof-of-concept agreement, they will effectively explore  combining their technology in search of insights about conditions including cancer, Parkinson's disease, and Wilson's disease, according to a spokesperson for Ann Arbor, Michigan-based Genomenon.

Pasadena, California-based Deep 6 AI offers software that mines structured and unstructured patient records, and genomics and pathology data to support trial-feasibility site selection and patient recruitment. That firm will integrate with Genomenon's AI-powered Genomic Landscapes platform to match patients to trial inclusion/exclusion criteria and then rank trial candidates by match percentage.

"Our collaboration with Deep 6 AI will help patients who will benefit from matching knowledge, while our Genomic Landscapes enable pharma to accelerate target discovery, identify genetic biomarkers for better clinical trial stratification, and develop [clinical diagnostics] for regulatory approval," Genomenon CEO Mike Klein said in a statement.

"Precision matching is at the heart of our mission to support precision medicine and rapidly deliver more targeted therapies to patients," said Jason Attanucci, Deep 6 AI's VP of life sciences. "Together, both Genomenon and Deep 6 AI will provide a combined, AI-driven understanding of disease, enabling actionable insight into their genetic drivers, clinical representation, and comorbidity."

Attanucci is scheduled to co-present at the CNS Summit Nov. 9 on results of a study highlighting Deep 6 AI's matching technology.

In September, Genomenon announced a partnership with AstraZeneca's Alexion Pharmaceuticals to apply Genomic Landscapes to diagnosis of rare diseases including Wilson's.

The Scan

Machine Learning Helps ID Molecular Mechanisms of Pancreatic Islet Beta Cell Subtypes in Type 2 Diabetes

The approach helps overcome limitations of previous studies that had investigated the molecular mechanisms of pancreatic islet beta cells, the authors write in their Nature Genetics paper.

Culture-Based Methods, Shotgun Sequencing Reveal Transmission of Bifidobacterium Strains From Mothers to Infants

In a Nature Communications study, culture-based approaches along with shotgun sequencing give a better picture of the microbial strains transmitted from mothers to infants.

Microbial Communities Can Help Trees Adapt to Changing Climates

Tree seedlings that were inoculated with microbes from dry, warm, or cold sites could better survive drought, heat, and cold stress, according to a study in Science.

A Combination of Genetics and Environment Causes Cleft Lip

In a study published in Nature Communications, researchers investigate what combination of genetic and environmental factors come into play to cause cleft lip/palate.